Bente Vestergaard

Bente Vestergaard

Auto-generated profile, based on publicly available information

Bente Vestergaard

Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in Nature
Verified
Journal Article
Closed access
URUrmila B. S. Rawat
Urmila B. S. Rawat
AZAndrey V. Zavialov
Andrey V. Zavialov
JSJayati Sengupta
Jayati Sengupta
MVMikel Valle
Mikel Valle
RGRobert A. Grassucci
Robert A. Grassucci
JFJoachim Frank
Joachim Frank

1 May 2007 in PLOS Biology
Verified
Journal Article
Open access
PDF file
BVBente Vestergaard
Bente Vestergaard
MGMinna Groenning
Minna Groenning
MRManfred Rössle
Manfred Rössle
JKJette S Kastrup
Jette S Kastrup
MWMarco van de Weert
Marco van de Weert
DSDmitri I. Svergun
Dmitri I. Svergun
Although amyloid fibrillation is generally believed to be a nucleation-dependent process, the nuclei are largely structurally uncharacterized. This is in part due to the inherent experimental challenge associated with structural descriptions of individual components in a dynamic multi-component equilibrium. There are indications that oligomeric aggregated precursors of fibrillation, and not mature fibrils, are the main cause of cytotoxicity in amyloid disease. This further emphasizes the importance of characterizing early fibrillation events. Here we present a kinetic x-ray solution scattering study of insulin fibrillation, revealing three major components: insulin monomers, mature fibrils, and an oligomeric species. Low-resolution three-dimensional structures are determined for the fibril repeating unit and for the oligomer, the latter being a helical unit composed of five to six insulin monomers. This helical oligomer is likely to be a structural nucleus, which accumulates above the supercritical concentration used in our experiments. The growth rate of the fibrils is proportional to the amount of the helical oligomer present in solution, suggesting that these oligomers elongate the fibrils. Hence, the structural nucleus and elongating unit in insulin amyloid fibrillation may be the same structural component above supercritical concentrations. A novel elongation pathway of insulin amyloid fibrils is proposed, based on the shape and size of the fibrillation precursor. The distinct helical oligomer described in this study defines a conceptually new basis of structure-based drug design against amyloid diseases. Diseases associated with the presence of amyloid structures, such as Alzheimer and Parkinson disease, are characterized by the presence of protein aggregates in the form of highly ordered fibrils. This amyloid fibril formation is also commonly observed for a number of protein drugs, such as insulin. Detailed information on how and why these fibrils are formed will be very useful to design compounds and drugs that may reverse or even prevent fibril formation, but existing knowledge in this field is still limited. We have studied, in real time, the fibril formation of insulin using a technique based on scattering of x-rays (small-angle x-ray scattering [SAXS]). Using SAXS, we obtained hitherto unprecedented three-dimensional structural information on these fibrils in solution. Most importantly, we were able to describe the three-dimensional structure of a crucial intermediate, which is probably a structural starting point (nucleus) in the fibril formation process. These results suggest that under our experimental conditions this crucial intermediate serves both as the fibrillation nucleus, as well as the elongating species. We propose that the latter intermediate is an interesting target for small molecules in order to prevent or reduce amyloid fibril formation.

8 August 2009 in Journal of Applied Crystallography
Verified
Journal Article
Closed access
PDF file
SNS. S. Nielsen
S. S. Nielsen
KTK. Noergaard Toft
K. Noergaard Toft
DSD. Snakenborg
D. Snakenborg
MJM. G. Jeppesen
M. G. Jeppesen
JJJ. K. Jacobsen
J. K. Jacobsen
LAL. Arleth
L. Arleth

7 February 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
LGLise Giehm
Lise Giehm
DSDmitri I. Svergun
Dmitri I. Svergun
DODaniel Otzen
Daniel Otzen
BVBente Vestergaard
Bente Vestergaard
One of the major hallmarks of Parkinson disease is aggregation of the protein α-synuclein (αSN). Aggregate cytotoxicity has been linked to an oligomeric species formed at early stages in the aggregation process. Here we follow the fibrillation process of αSN in solution over time using small angle X-ray scattering and resolve four major coexisting species in the fibrillation process, namely monomer, dimer, fibril and an oligomer. By ab initio modeling to fit the data, we obtain a low-resolution structure of a symmetrical and slender αSN fibril in solution, consisting of a repeating unit with a maximal distance of 900 Å and a diameter of ∼180 Å . The same approach shows the oligomer to be shaped like a wreath, with a central channel and with dimensions corresponding to the width of the fibril. The structure, accumulation and decay of this oligomer is consistent with an on-pathway role for the oligomer in the fibrillation process. We propose an oligomer-driven αSN fibril formation mechanism, where the fibril is built from the oligomers. The wreath-shaped structure of the oligomer highlights its potential cytotoxicity by simple membrane permeabilization. This is confirmed by the ability of the purified oligomer to disrupt liposomes. Our results provide the first structural description in solution of a potentially cytotoxic oligomer, which accumulates during the fibrillation of αSN.

1 December 2001 in Molecular Cell
Verified
Journal Article
Closed access
BVBente Vestergaard
Bente Vestergaard
LVLan Bich Van
Lan Bich Van
GAGregers R. Andersen
Gregers R. Andersen
JNJens Nyborg
Jens Nyborg
RBRichard H Buckingham
Richard H Buckingham
MKMorten Kjeldgaard
Morten Kjeldgaard

17 February 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
ABAnders Bach
Anders Bach
BCBettina Hjelm Clausen
Bettina Hjelm Clausen
MMMagda Møller
Magda Møller
BVBente Vestergaard
Bente Vestergaard
CCCelestine N. Chi
Celestine N. Chi
KSKristian Strømgaard
Kristian Strømgaard
Inhibition of the ternary protein complex of the synaptic scaffolding protein postsynaptic density protein-95 (PSD-95), neuronal nitric oxide synthase (nNOS), and the N -methyl- d -aspartate (NMDA) receptor is a potential strategy for treating ischemic brain damage, but high-affinity inhibitors are lacking. Here we report the design and synthesis of a novel dimeric inhibitor, Tat- N PEG4(IETDV) 2 (Tat- N -dimer), which binds the tandem PDZ1-2 domain of PSD-95 with an unprecedented high affinity of 4.6 nM, and displays extensive protease-resistance as evaluated in vitro by stability-measurements in human blood plasma. X-ray crystallography, NMR, and small-angle X-ray scattering (SAXS) deduced a true bivalent interaction between dimeric inhibitor and PDZ1-2, and also provided a dynamic model of the conformational changes of PDZ1-2 induced by the dimeric inhibitor. A single intravenous injection of Tat- N -dimer (3 nmol/g) to mice subjected to focal cerebral ischemia reduces infarct volume with 40% and restores motor functions. Thus, Tat- N -dimer is a highly efficacious neuroprotective agent with therapeutic potential in stroke.